Newron Pharmaceuticals S.p.A.
NP5
株式のランク
#17870
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
株価
$10.32
時価総額
$211.01M
変化（1日）
-2.25%
変化（1年）
-40.13%
国
IT
取引 Newron Pharmaceuticals S.p.A. (NP5)
カテゴリー
Healthcare
の時価総額 Newron Pharmaceuticals S.p.A.(NP5)
時価総額: $211.01M
October 2026時点で、Newron Pharmaceuticals S.p.A. の時価総額は $211.01M です。これは、当社のデータによると、Newron Pharmaceuticals S.p.A. が世界で17870th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Newron Pharmaceuticals S.p.A. の時価総額の履歴（2015 から 2026 まで）
